Provided by Tiger Trade Technology Pte. Ltd.

Lixte Biotechnology Holdings Inc.

5.76
-0.1500-2.54%
Volume:77.44K
Turnover:438.50K
Market Cap:71.33M
PE:-5.01
High:6.02
Open:5.93
Low:5.30
Close:5.91
52wk High:6.26
52wk Low:0.6400
Shares:12.38M
Float Shares:11.87M
Volume Ratio:1.07
T/O Rate:0.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1500
EPS(LYR):-1.2600
ROE:-140.99%
ROA:-64.50%
PB:8.98
PE(LYR):-4.57

Loading ...

Lixte Biotechnology Q1 EPS USD -0.18

THOMSON REUTERS
·
May 15

Lixte Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update

THOMSON REUTERS
·
May 15

Lixte Biotechnology Q1 FY26 net loss widens to $1.99 million; operating loss widens to $1.99 million

Reuters
·
May 15

LIXTE Biotechnology Holdings (NASDAQ: LIXT) Unlocking New Potential in Precision Cancer Treatment

TIPRANKS
·
Apr 28

Greenland Mines appoints Jason D. Sawyer to board of directors

Reuters
·
Apr 23

LIXTE Biotechnology Holdings (NASDAQ: LIXT) Positions LB-100 as Novel Approach in Cancer Treatment Landscape

TIPRANKS
·
Apr 21

Lixte Biotechnology replaces stock options with RSUs for executives, directors

Reuters
·
Apr 18

LIXTE Biotechnology (NASDAQ: LIXT) Reports Interim Ovarian Cancer Trial Results at SGO Conference

TIPRANKS
·
Apr 14

Lixte reports favorable interim results for LB-100 plus dostarlimab ovarian cancer trial

Reuters
·
Apr 13

Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference

THOMSON REUTERS
·
Apr 13

Lixte Biotech Holdings (NASDAQ: LIXT) Advances Precision Oncology Strategy with LB-100, Expands Clinical and Strategic Partnerships

TIPRANKS
·
Apr 11

LIXTE Biotechnology Holdings (NASDAQ: LIXT) Files 2025 Form 10-K, Highlights Transformational Year

TIPRANKS
·
Apr 02

LIXTE Biotechnology (NASDAQ: LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials

TIPRANKS
·
Apr 01

Lixte FY25 net loss widens to $6M; operating loss climbs to $5.1M

Reuters
·
Apr 01

Lixte Biotech (NASDAQ: LIXT) Advances Precision Oncology with LB-100, Strengthens Position Through Liora Technologies Partnership

TIPRANKS
·
Mar 28

LIXTE Biotechnology (NASDAQ: LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape

TIPRANKS
·
Mar 24

Lixte Biotechnology Raises CEO Compensation Amid Leadership Support

TIPRANKS
·
Mar 21

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:42 AM

Reuters
·
Mar 12

Lixte Amends Share Exchange, Clarifies Liora Ownership Structure

TIPRANKS
·
Mar 11

LIXTE Biotechnology Holdings (NASDAQ: LIXT) Adds Innovative LiGHT Therapy to Pipeline

TIPRANKS
·
Mar 11